Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
10:29am, Thursday, 04'th Dec 2025
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial la
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%
04:10am, Sunday, 30'th Nov 2025
Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.
The Best Stocks to Buy With $1,000 Right Now
01:23pm, Saturday, 29'th Nov 2025
It may be the spawn of a company that faded into irrelevancy, but GE Vernova is thriving as a standalone outfit. Most investors may not appreciate just how long it takes CRISPR Therapeutics to complet
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Tuesday, 25'th Nov 2025
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
04:31am, Friday, 21'st Nov 2025
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
06:05am, Wednesday, 19'th Nov 2025
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also c
4 Struggling Stocks With “Harmless” Pullbacks
11:05am, Tuesday, 18'th Nov 2025
Subscribers to Chart of the Week received this commentary on Sunday, November 16.
Bedell Frazier Investment Counselling LLC Sells 7,118 Shares of CRISPR Therapeutics AG $CRSP
04:20am, Tuesday, 18'th Nov 2025
Bedell Frazier Investment Counselling LLC trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ: CRSP) by 48.2% during the second quarter, according to its most recent disclosure with the Secu
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of “Hold” from Brokerages
02:00am, Tuesday, 18'th Nov 2025
CRISPR Therapeutics AG (NASDAQ: CRSP - Get Free Report) has been given an average rating of "Hold" by the twenty-one research firms that are covering the firm, MarketBeat.com reports. Two research ana
1 Underrated Stock That Could Soar by 58%, According to Wall Street
06:53am, Monday, 17'th Nov 2025
CRISPR Therapeutics' sole approved product doesn't generate much sales yet. It does have some pipeline candidates that could make progress over the next year.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 14'th Nov 2025
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy
03:43pm, Thursday, 13'th Nov 2025
CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad appr
ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?
05:04pm, Wednesday, 12'th Nov 2025
Ark Investment sold 395,617 shares worth about $25 million. It represents a minor change in its 13F assets under management (AUM).
Cathie Wood doubles down on Alibaba: ARK Invest snaps up $25M in Chinese tech stocks
07:02am, Wednesday, 12'th Nov 2025
ARK Invest funds boosted holdings in Alibaba (BABA) and Baidu (BIDU) while trimming stakes in Reddit (RDDT), Exact Sciences (EXAS) and Iridium Communications (I
CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates
10:01am, Tuesday, 11'th Nov 2025
CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.
